CASI Pharmaceuticals, Inc.
CASI
$1.94
$0.22713.27%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -15.77% | -47.82% | -47.07% | -31.73% | -21.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -15.77% | -47.82% | -47.07% | -31.73% | -21.41% |
| Cost of Revenue | 25.78% | -34.06% | -37.18% | -21.98% | -12.64% |
| Gross Profit | -44.41% | -55.61% | -52.72% | -37.32% | -26.50% |
| SG&A Expenses | -0.94% | -2.40% | -9.32% | 4.63% | 10.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 99.97% | -287.44% | -287.44% | -- | -- |
| Total Operating Expenses | 14.52% | -20.92% | -26.26% | -18.44% | -15.00% |
| Operating Income | -55.11% | -23.45% | -7.72% | -2.85% | 4.57% |
| Income Before Tax | -49.04% | 18.59% | 30.01% | 15.88% | 31.19% |
| Income Tax Expenses | -- | -100.05% | -100.05% | -104.09% | -104.09% |
| Earnings from Continuing Operations | -49.50% | 22.48% | 33.31% | 20.51% | 34.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 77.11% | 53.95% | 32.21% | 10.30% |
| Net Income | -45.73% | 23.45% | 33.68% | 20.74% | 34.32% |
| EBIT | -55.11% | -23.45% | -7.72% | -2.85% | 4.57% |
| EBITDA | -59.02% | -21.71% | -6.37% | -1.12% | 6.40% |
| EPS Basic | -25.16% | 25.72% | 33.26% | 19.59% | 32.90% |
| Normalized Basic EPS | -43.46% | -24.14% | -4.90% | -19.26% | -1.02% |
| EPS Diluted | -25.07% | 25.68% | 33.21% | 19.55% | 32.86% |
| Normalized Diluted EPS | -43.46% | -24.14% | -4.90% | -19.26% | -1.02% |
| Average Basic Shares Outstanding | 14.80% | 3.59% | -0.40% | -1.21% | -2.11% |
| Average Diluted Shares Outstanding | 14.80% | 3.59% | -0.40% | -1.21% | -2.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |